Cargando…
An Open-Label Pilot Study of Adrenocorticotrophic Hormone in the Treatment of IgA Nephropathy at High Risk of Progression
INTRODUCTION: IgA nephropathy (IgAN) is the most common glomerulonephritis with high risk of progression to end-stage renal disease in patients with proteinuria >1 g/24 hours. There are no known effective treatments in patients with IgAN. METHODS: We conducted a prospective open-label pilot study...
Autores principales: | Zand, Ladan, Canetta, Pietro, Lafayette, Richard, Aslam, Nabeel, Jan, Novak, Sethi, Sanjeev, Fervenza, Fernando C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943772/ https://www.ncbi.nlm.nih.gov/pubmed/31922061 http://dx.doi.org/10.1016/j.ekir.2019.10.007 |
Ejemplares similares
-
Noninvasive Urinary Monitoring of Progression in IgA Nephropathy
por: Yang, Joshua Y. C., et al.
Publicado: (2019) -
Toward a Clearer Picture of IgA Nephropathy in Spondyloarthritis
por: Canetta, Pietro
Publicado: (2020) -
A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy
por: Hladunewich, Michelle A., et al.
Publicado: (2014) -
Mechanism of Control of Adrenocorticotrophic Hormone
por: McDermott, W. V., et al.
Publicado: (1950) -
Adrenocorticotrophic hormone secreting pheochromocytoma
por: Ramasamy, Meyyappan M., et al.
Publicado: (2010)